Navigation Links
NIH, DOD grants to fund prostate cancer, diabetes research at UH
Date:6/27/2012

HOUSTON, June 26, 2012 Researchers at the University of Houston (UH) have been awarded more than $862,000 in federal grants to pursue projects related to prostate cancer, diabetes and obesity. The U.S. Department of Defense (DOD) and National Institutes of Health (NIH) will fund two new prostate cancer projects, while a third NIH grant will support diabetes and obesity research in the UH Center for Nuclear Receptors and Cell Signaling (CNRCS). The center's research projects now account for eight active NIH grants, a key indicator in Tier One rankings.

"Success in today's competitive federal funding landscape is validation of the motivation and ingenuity of our researchers," said Dr. Jan-ke Gustafsson, director of CNRCS. "With these new awards we are now able to explore new avenues of investigation into the treatment and prevention of these important diseases."

The DOD awarded a grant of more than $337,000 this month to fund assistant professor Daniel Frigo's project, "CaMKK beta-AMPK Signaling Axis as a Biomarker and Therapeutic Target for Advanced Prostate Cancer." Prostate cancer, the second most common cancer in American men, is a major research focus of the Frigo laboratory. The award will further the team's work with CaMKK beta-AMPK, a signaling pathway that may be an effective target for treating prostate cancer. The project is scheduled to begin by the end of June.

"Grants are critical to our research, not only for funding but also building and maintaining a reputable track record on the national level," said Frigo. "Our team is eager to begin these new projects as we focus on identifying drug targets for possible clinical trials in the next phases of research."

Last month, Frigo additionally was awarded a $150,000 grant from the NIH's National Cancer Institute to expand his established research involving the treatment and prevention of prostate cancer. The project, "Modulation of Branched-Chain Fatty Acids for the Prevention of Prostate Cancer," will examine how the convergence of specific biological cues and our diets may function to promote cancer and could provide guidance for preventing the disease. The project is Frigo's third to be funded by the NIH, since joining the center in 2010.

Gustafsson also was notified recently of another NIH grant that will support expanded uses for the center's state-of-the-art zebrafish laboratory. The National Institute of Environmental Health Sciences awarded his team more than $375,000 to collaborate with UH computer science professor Ioannis Kakadiaris on diabetes and obesity research. The project is expected to be led by Maria Bondesson, a research assistant professor with the center. The project, "Detection of Obesogens and Diabetogens by Zebrafish Screening Models," will entail screening the effects of chemical compounds that may disrupt the development of the endocrine system. It is widely hypothesized that exposure to certain chemical compounds in developed countries may be responsible for the steady increase in obesity and diabetes in the U.S.

In total, the CNRCS has 27 active grants. Overall, the center's active projects account for more than $18 million in research funding at UH, another significant metric for Tier One status. Established in 2009, CNRCS is a focal point of the UH health initiative. The center's investigators are involved in many aspects of nuclear receptor research and focused on understanding the roles of these receptors in health and disease. Cell signaling is part of a complex system of communication where cells signal each other to decide when to generate new cells. Errors in this processing are responsible for the diseases they study.


'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert  

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. 2 Grand Challenges Explorations grants for global health
3. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
4. New drug prevents spread of human prostate cancer cells
5. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Study examines adverse effects among different radiation therapies for prostate cancer
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. Warren Buffett Has Early Stage Prostate Cancer
10. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
11. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH, DOD grants to fund prostate cancer, diabetes research at UH
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... simulation -centric training, today announced the launch of a new research study, The ... the skills needed to execute that strategy, and the actual success of achieving ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
(Date:3/27/2017)... Texas , March 27, 2017   Genprex, Inc. , ... that Julien Pham , MD, the Company,s Chief Operating Officer, ... investor conferences. Sachs 5th Annual Cancer BioPartnering & ... New York, NY ... BioCentury 24th Annual Future Leaders in ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators ... $724 million by 2022, growing at a CAGR of 3.6% during the forecast ... ... Allied Market Research Logo ...
Breaking Medicine Technology: